Suiza - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

advanced accelerator applications international sa - gozetotidum - trousse pour préparation radiopharmaceutique - gozetotidum 25 µg, natrii acetas trihydricus, natrii chloridum, acidum gentisicum, pro vitro corresp. natrium 28.97 mg. - diagnostique tep du cancer de la prostate psma-positif - radiopharmazeutika

Unión Europea - italiano - EMA (European Medicines Agency)

novartis europharm limited  - gozetotide - imaging dei radionuclidi - radiofarmaci diagnostici - questo medicinale è solo per uso diagnostico. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.

Unión Europea - italiano - EMA (European Medicines Agency)

curium pet france - piflufolastat (18f) - neoplasie prostatiche - radiofarmaci diagnostici - questo medicinale è solo per uso diagnostico. pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent. pylclari is indicated for use with positron emission tomography (pet).